New certifying board to credential healthcare workers in AI

The newly incorporated American Board of Artificial Intelligence in Medicine (ABAIM) is soon to begin credentialing healthcare workers in AI, machine learning and deep learning.

The group announced its intentions March 9, noting that it was only recently incorporated as a not-for-profit entity.

ABAIM’s main activity will be awarding board certification to individuals who pass an exam demonstrating a firm grasp of advanced concepts related to AI and its iterations used in healthcare.  

The certification also will validate the ability of those so certified to analyze the benefits and pitfalls of these technologies in real-world scenarios.

The ABAIM says its ultimate goal is to “enable healthcare professionals to participate in development, assessment, selection and implementation of AI, machine learning and deep learning tools for their benefit and that of the institutions they serve today and in the future.”

Two physicians are serving as the board’s chairs and driving the initiative: Orest Boyko, MD, PhD, a psychology research professor at the University of Southern California; and Anthony Chang, MD, of the Sharon Disney Lund Medical Intelligence and Innovation Institute (MI3) at Children’s Hospital of Orange County in California.

Artificial Intelligence and its related technologies are “increasingly important to healthcare as a whole,” Boyko said.

Chang added that ABAIM has a modular curriculum that will enable a wide range of healthcare professionals—as well as patients, data scientists and IT personnel—to become knowledgeable in the application of AI, ML and DL tools and technologies.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.